ZSCAN18: A Potential Drug Target and Biomarker (G65982)

Target Name: ZSCAN18

NCBI ID: G65982

ZSCAN18

Other Name(s): Zinc finger and SCAN domain-containing protein 18 | Zinc finger and SCAN domain containing 18, transcript variant 1 | FLJ38919 | MGC2427 | zinc finger protein 447 | MGC8682 | FLJ44152 | Zinc finger and SCAN domain-containing protein 18 (isoform 1) | zinc finger and SCAN domain containing 18 | ZSC18_HUMAN | ZNF447 | MGC4074 | ZSCAN18 variant 1 | DKFZp586B1122 | Zinc finger protein 447 | FLJ12895

ZSCAN18: A Potential Drug Target and Biomarker

Zinc finger and SCAN domain-containing protein 18 (ZSCAN18) is a protein that has been identified as a potential drug target and biomarker. ZSCAN18 is a key regulator of cell growth and differentiation, and its dysfunction has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The ZSCAN18 protein is composed of 21 different proteins that are encoded by the gene ZSCN18. ZSCN18 is expressed in most tissues of the body and plays a critical role in regulating cell growth, differentiation, and survival. The ZSCAN18 protein functions as a scaffold protein that helps to maintain the stability of the cytoskeleton and acts as a receptor for various signaling pathways.

One of the key functions of ZSCAN18 is its ability to interact with and regulate the activity of other proteins. ZSCAN18 has been shown to interact with a wide range of proteins, including cytoskeletal components, transcription factors, and signaling molecules. These interactions allow ZSCAN18 to regulate the growth and differentiation of various cell types and have implications for the development of cancer and other diseases.

In addition to its role in cell regulation, ZSCAN18 has also been shown to play a key role in the development and progression of diseases. For example, ZSCAN18 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. In addition, ZSCAN18 has also been implicated in the development of certain autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

Given its involvement in the regulation of cell growth and the development of diseases, ZSCAN18 is a promising target for drug development. Researchers have identified several potential drug compounds that can inhibit the activity of ZSCAN18 and are currently in the process of testing these compounds for their potential utility as treatments for various diseases.

In addition to its potential as a drug target, ZSCAN18 has also been identified as a potential biomarker. The ZSCAN18 protein is expressed in most tissues of the body and can be used as a protein biomarker for a wide range of diseases. For example, researchers have used ZSCAN18 to diagnose and monitor the progression of certain diseases, such as cancer. In addition, ZSCAN18 has also been used as a biomarker for tracking the effectiveness of certain treatments, such as chemotherapy.

Overall, ZSCAN18 is a protein that has significant implications for the development of drugs and biomarkers for a wide range of diseases. Further research is needed to fully understand the function and potential of ZSCAN18 and its implications for human health.

Protein Name: Zinc Finger And SCAN Domain Containing 18

Functions: May be involved in transcriptional regulation

The "ZSCAN18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZSCAN18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets